Baptist Heart & Vascular Institute Research
The research department has two upcoming PCSK9 inhibitor trials. The first trial is evaluating the effect of treatment with a PCSK9 inhibitor compared to placebo on the risk of coronary heart disease, death, myocardial infarction or ischemic stroke in subjects at high cardiovascular risk without prior MI or stroke and receiving optimized lipid-lowering therapy.
The primary objective of the second PCSK9 inhibitor trial is to evaluate the effectiveness of PCSK9 inhibitors to reduce cardiovascular events among subjects with a recent atherosclerotic cardiovascular event or revascularization. Effectiveness will be evaluated by collection of prospective observational data.
PCSK9 inhibitors were approved by the FDA in 2015 to lower LDL. The drug is a monoclonal immunoglobulin that specifically binds to PCSK9 preventing its interaction with LDLR. The inhibition of PCSK9 leads to increased LDLR expression and subsequent decreased LDL-C.
If you would like further information about our research program, please call 850-484-6690.